Volume 12 Issue 2
Mar.  2021
Turn off MathJax
Article Contents
Zheng Shanshan, Liu Sheng. Discussion on heart transplantation indications in patients with end-stage heart failure complicated with reversible pulmonary artery hypertension[J]. ORGAN TRANSPLANTATION, 2021, 12(2): 239-243. doi: 10.3969/j.issn.1674-7445.2021.02.017
Citation: Zheng Shanshan, Liu Sheng. Discussion on heart transplantation indications in patients with end-stage heart failure complicated with reversible pulmonary artery hypertension[J]. ORGAN TRANSPLANTATION, 2021, 12(2): 239-243. doi: 10.3969/j.issn.1674-7445.2021.02.017

Discussion on heart transplantation indications in patients with end-stage heart failure complicated with reversible pulmonary artery hypertension

doi: 10.3969/j.issn.1674-7445.2021.02.017
More Information
  • Corresponding author: Liu Sheng, Email: liusheng1999@msn.com
  • Received Date: 2020-11-30
    Available Online: 2021-03-19
  • Publish Date: 2021-03-15
  • Heart transplantation can save the life and improve the quality of life of patients with end-stage heart failure. Nevertheless, it is not suitable for all patients with end-stage heart failure. As a common complication of end-stage heart failure, pulmonary artery hypertension may increase the incidence of right heart failure after heart transplantation, which is associated with the short- and long-term fatality risk in the recipients after heart transplantation. In clinical practice, different transplant centers have different criteria for heart transplantation indications in patients with end-stage heart failure complicated with pulmonary artery hypertension. Accurate preoperative evaluation of surgical indications plays a critical role in determining the success of heart transplantation. In this article, the definition, pathogenesis and effects on heart transplantation, diagnostic methods and reversibility judgment of pulmonary artery hypertension, diagnostic treatment of reversible pulmonary artery hypertension and indications of heart transplantation in patients with end-stage heart failure complicated with reversible pulmonary hypertension were reviewed.

     

  • loading
  • [1]
    CRAWFORD TC, LEARY PJ, FRASER CD 3RD, et al. Impact of the new pulmonary hypertension definition on heart transplant outcomes: expanding the hemodynamic risk profile[J]. Chest, 2020, 157(1): 151-161. DOI: 10.1016/j.chest.2019.07.028.
    [2]
    GALIÈ N, HUMBERT M, VACHIERY JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Rev Esp Cardiol (Engl Ed), 2016, 69(2): 177. DOI: 10.1016/j.rec.2016.01.002.
    [3]
    MEHRA MR, KOBASHIGAWA J, STARLING R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006[J]. J Heart Lung Transplant, 2006, 25(9): 1024-1042. DOI: 10.1016/j.healun.2006.06.008.
    [4]
    MEHRA MR, CANTER CE, HANNAN MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update[J]. J Heart Lung Transplant, 2016, 35(1): 1-23. DOI: 10.1016/j.healun.2015.10.023.
    [5]
    中华医学会器官移植学分会. 中国心脏移植受者术前评估与准备技术规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(1): 1-7. DOI: 10.3877/cma.j.issn.1674-3903.2019.01.001

    Branch of Organ Transplantation of Chinese Medical Association. Technical specifications for preoperative evaluation and preparation for heart transplant recipients in China (2019 edition)[J/CD]. Chin J Transplant (Electr Edit), 2019, 13(1): 1-7. DOI: 10.3877/cma.j.issn.1674-3903.2019.01.001.
    [6]
    陈军, 魏翔. 合并肺动脉高压的心脏移植[J]. 临床外科杂志, 2018, 26(12): 896-899. DOI: 10.3969/j.issn.1005-6483.2018.12.002.

    CHEN J, WEI X. Heart transplantation with pulmonary hypertension[J]. J Clin Surg, 2018, 26(12): 896-899. DOI: 10.3969/j.issn.1005-6483.2018.12.002.
    [7]
    MARTENS P, BELIËN H, DUPONT M, et al. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction[J]. Cardiovasc Ther, 2018, 36(4): e12435. DOI: 10.1111/1755-5922.12435.
    [8]
    STRONG C, RAPOSO L, CASTRO M, et al. Haemodynamic effects and potential clinical implications of inhaled nitric oxide during right heart catheterization in heart transplant candidates[J]. ESC Heart Fail, 2020, 7(2): 673-681. DOI: 10.1002/ehf2.12639.
    [9]
    DELGADO JF, CONDE E, SÁNCHEZ V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure[J]. Eur J Heart Fail, 2005, 7(6): 1011-1016. DOI: 10.1016/j.ejheart.2004.10.021.
    [10]
    KONSTAM MA, KIERNAN MS, BERNSTEIN D, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association[J]. Circulation, 2018, 137(20): e578-e622. DOI: 10.1161/CIR.0000000000000560.
    [11]
    SCARDULLA F, BELLAVIA D, VITULO P, et al. Biomechanical determinants of right ventricular failure in pulmonary hypertension[J]. ASAIO J, 2018, 64(4): 557-564. DOI: 10.1097/MAT.0000000000000683.
    [12]
    陈伟, 姜桢. 可逆性肺高压在行原位心脏移植术中的危险性分析[J]. 复旦学报(医学版), 2006, 33(5): 635-638. DOI: 10.3969/j.issn.1672-8467.2006.05.015.

    CHEN W, JIANG Z. Retrospective study on risk factors of reversible pulmonary hypertension in heart transplantation recipients[J]. Fudan Univ J Med Sci, 2006, 33(5): 635-638. DOI: 10.3969/j.issn.1672-8467.2006.05.015.
    [13]
    RIVINIUS R, HELMSCHROTT M, RUHPARWAR A, et al. Elevated pre-transplant pulmonary vascular resistance is associated with early post-transplant atrial fibrillation and mortality[J]. ESC Heart Fail, 2020, 7(1): 176-187. DOI: 10.1002/ehf2.12549.
    [14]
    BOUCLY A, WEATHERALD J, SAVALE L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension[J]. Eur Respir J, 2017, 50(2): 1700889. DOI: 10.1183/13993003.00889-2017.
    [15]
    KRISHNAMURTHY Y, COOPER LB, LU D, et al. Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States[J]. J Heart Lung Transplant, 2016, 35(5): 619-624. DOI: 10.1016/j.healun.2015.12.017.
    [16]
    CANTERO-PÉREZ EM, SAYAGO I, SOBRINO-MÁRQUEZ JM, et al. Impact of preoperative pulmonary hypertension on survival in patients undergoing elective heart transplant[J]. Transplant Proc, 2020, 52(2): 580-583. DOI: 10.1016/j.transproceed.2019.11.034.
    [17]
    TRUBY LK, DEROO S, SPELLMAN J, et al. Management of primary graft failure after heart transplantation: preoperative risks, perioperative events, and postoperative decisions[J]. Clin Transplant, 2019, 33(6): e13557. DOI: 10.1111/ctr.13557.
    [18]
    BUTLER J, STANKEWICZ MA, WU J, et al. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation[J]. J Heart Lung Transplant, 2005, 24(2): 170-177. DOI: 10.1016/j.healun.2003.09.045.
    [19]
    SCHUMER EM, GALLO M, ROGERS MP, et al. The development of pulmonary hypertension results in decreased post-transplant survival[J]. ASAIO J, 2018, 64(4): 508-514. DOI: 10.1097/MAT.0000000000000682.
    [20]
    KURZYNA M, ARASZKIEWICZ A, BŁASZCZAK P, et al. Summary of recommendations for the haemodynamic and angiographic assessment of the pulmonary circulation. joint statement of the Polish Cardiac Society's Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions[J]. Kardiol Pol, 2015, 73(1): 63-68. DOI: 10.5603/KP.2015.0011.
    [21]
    肖丹, 张毅, 徐大春, 等. 左心功能不全继发的肺动脉高压[J]. 现代生物医学进展, 2013, 13(34): 6781-6785.

    XIAO D, ZHANG Y, XU DC, et al. Pulmonary hypertension secondary to left heart dysfunction: a review[J]. Prog Mod Biomed, 2013, 13(34): 6781-6785.
    [22]
    SELIM AM, WADHWANI L, BURDORF A, et al. Left ventricular assist devices in pulmonary hypertension group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure[J]. Heart Lung Circ, 2019, 28(6): 946-952. DOI: 10.1016/j.hlc.2018.04.299.
    [23]
    MOAYEDIFAR R, ZUCKERMANN A, ALIABADI-ZUCKERMANN A, et al. Long-term heart transplant outcomes after lowering fixed pulmonary hypertension using left ventricular assist devices[J]. Eur J Cardiothorac Surg, 2018, 54(6): 1116-1121. DOI: 10.1093/ejcts/ezy214.
    [24]
    ANDO M, TAKAYAMA H, KURLANSKY PA, et al. Effect of pulmonary hypertension on transplant outcomes in patients with ventricular assist devices[J]. Ann Thorac Surg, 2020, 110(1): 158-164. DOI: 10.1016/j.athoracsur.2019.09.095.
    [25]
    KETTNER J, DORAZILOVÁ Z, NETUKA I, et al. Is severe pulmonary hypertension a contraindication for orthotopic heart transplantation? not any more[J]. Physiol Res, 2011, 60(5): 769-775. DOI: 10.33549/physiolres.932158.
    [26]
    SULTAN S, TSENG S, STANZIOLA AA, et al. Pulmonary hypertension: the role of lung transplantation[J]. Heart Fail Clin, 2018, 14(3): 327-331. DOI: 10.1016/j.hfc.2018.02.007.
    [27]
    AMMIRATI E, OLIVA F, CANNATA A, et al. Current indications for heart transplantation and left ventricular assist device: a practical point of view[J]. Eur J Intern Med, 2014, 25(5): 422-429. DOI: 10.1016/j.ejim.2014.02.006.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (356) PDF downloads(45) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return